48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse

Table 3

Independent variables associated with retreatment in GEE models.

Parameters	Univariate		Multivariate
	OR (95% CI)		OR (95% CI)
Sex
Male	Ref	-	Ref	-
Female	1.75 (0.42–7.35)	0.445	2.17 (0.45–10.43)	0.332
Age, year	1.06 (0.98–1.14)	0.177	1.04 (0.92–1.18)	0.490
BMI, kg/m^2	1.00 (0.80–1.26)	0.975	1.02 (0.78–1.34)	0.878
Duration of NA treatment, year	1.25 (0.81–1.95)	0.314	1.08 (0.53–2.20)	0.830
Duration of negative HBV DNA maintenance, year	1.45 (0.90–2.33)	0.130	1.11 (0.42–2.91)	0.830
HBV DNA, (IU/mL)	1.28 (1.08–1.50)	0.003	1.34 (1.13–1.58)	<0.001
HBsAg, (IU/mL)	0.69 (0.26–1.83)	0.460	0.64 (0.24–1.72)	0.382
Origin HBeAg
Negative	Ref	-	Ref	-
Positive	1.07 (0.30–3.80)	0.921	1.23 (0.17–8.93)	0.838